No evidence is available on the transport of biliary biliary route) may be increased in certain pathological urate and the possible role of choleretic agents in the conditions such as uremia. 2,3 In addition, several facregulation of biliary urate elimination in humans. To tors such as extracellular fluid volume, urine flow rate, test this hypothesis we studied the following: (1) 45 cho-alcohol, food components, many medications (mainly lecystomized patients to determine urate levels in he-pyrazinamide and probenecid), and hormones alter patic bile and gallbladder bile, and (2) 13 cholecysto-urate kidney transport. 4 Assuming that the physiologimized patients fitted with T-tubes to determine the cal processes of bile secretion and urine excretion share effects of secretin injection (either 70 U of porcine secre-many similarities, biliary urate transport may be modi- urate comes mainly from secreted compound, the filof a significant increase in mean bile flow (P õ .001), whereas the mean biliary urate concentration signifi-tered urate representing a percentage of less than 10% cantly decreased (P õ .001) with a concomitant decrease of the excreted amount. 6 On the other hand, the biliary in the mean serum urate concentration (P õ .02). Manni-transport of urate has not, to our knowledge, been pretol also induced a significant increase in the mean urate viously investigated. In view of the fact that extrarenal clearance (P õ .002) because of a significant increase in urate elimination (including the biliary elimination the mean biliary urate concentration (P õ .01) with a route) may be important in some of the previously menconcomitant decrease in the mean serum urate concen-tioned pathological conditions, we sought to investigate tration (P õ .01) and without changes in the mean bile the biliary urate clearance (1)

The study describes the changes in basic hemodynamic parameters after long-term antihypertensive therapy with cilazapril - a new ACE inhibitor lacking a sulfhydryl group - in hypertensive patients and the drug effects on renal function, glucose tolerance and lipid metabolism. 30 patients (18 males, 12 females, mean age: 53.3 ± 18 years) with mild to moderate essential hypertension were studied. The following determinations were performed in patients, before and after 4.5 months of cilazapril monotherapy at a dose of 5 mg/24 h: (a) antihypertensive action of the drug (arterial pressure at rest and during a 24-hour recording); drug effects on left ventricular (LV) mass index; its contractility indexes (%FS, EF) and the left atrial emptying index were studied by means of echocardiography; plasma insulin concentration during oral glucose tolerance tests, in the fasting state, after the administration of 75 g glucose per os, as well as the changes in the insulinogenic index and the 6-keto-PGF_1α/TXB₂ ratio, and drug effect on renal function (urea, creatinine, uric acid, plasma electrolytes), blood lipid profile (total cholesterol, triglycerides, HDL-CH) and serum transaminases. Long-term drug administration exhibits an effective antihypertensive action, without causing reflex tachycardia and also reduces the LV mass index without affecting its EF, while improving its diastolic function. It does not significantly affect the various biochemical parameters, and achieves glucose regulation, both in the fasting state and after glucose loading, with a decrease in the insulinogenic index, and simultaneously increases the 6-keto-PGF_1α/TXB₂ ratio. The existence of a direct cause-effect relationship between the changes in the above hormone systems is possible.

No abstract